|Videos|November 26, 2013
Episode 4 - Treatment Guidelines and Economic Considerations
Advertisement
Episodes in this series
During this segment, Raoul S. Concepcion, MD, explains how the rapid development of agents for castration-resistant prostate cancer (CRPC) has led to an expanding number of clinical guidelines, developed by multiple organizations, for clinicians’ use during important treatment-decisions.
However, he explains that the treatment options recommended in these guidelines are expensive, creating a challenge to both clinicians and payers.
To clarify misconceptions about medical policy and coverage for patients with CRPC, Michael Kolodziej, MD, discusses the variables that payers consider when making decisions about coverage for these expensive treatment options.
Advertisement
Related to this article
Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.
FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.
Trial, transplant equity gaps in AML; Texas Medicaid funding dispute; pediatric GLP-1 access gaps; earlier biologic use; eye care restores vision.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Designing Effective Value-Based Oncology Models: Lalan Wilfong, MD
5